» Articles » PMID: 38357641

Unlocking the Potential of Big Data and AI in Medicine: Insights from Biobanking

Overview
Specialty General Medicine
Date 2024 Feb 15
PMID 38357641
Authors
Affiliations
Soon will be listed here.
Abstract

Big data and artificial intelligence are key elements in the medical field as they are expected to improve accuracy and efficiency in diagnosis and treatment, particularly in identifying biomedically relevant patterns, facilitating progress towards individually tailored preventative and therapeutic interventions. These applications belong to current research practice that is data-intensive. While the combination of imaging, pathological, genomic, and clinical data is needed to train algorithms to realize the full potential of these technologies, biobanks often serve as crucial infrastructures for data-sharing and data flows. In this paper, we argue that the 'data turn' in the life sciences has increasingly re-structured major infrastructures, which often were created for biological samples and associated data, as predominantly data infrastructures. These have evolved and diversified over time in terms of tackling relevant issues such as harmonization and standardization, but also consent practices and risk assessment. In line with the datafication, an increased use of AI-based technologies marks the current developments at the forefront of the big data research in life science and medicine that engender new issues and concerns along with opportunities. At a time when secure health data environments, such as European Health Data Space, are in the making, we argue that such meta-infrastructures can benefit both from the experience and evolution of biobanking, but also the current state of affairs in AI in medicine, regarding good governance, the social aspects and practices, as well as critical thinking about data practices, which can contribute to trustworthiness of such meta-infrastructures.

Citing Articles

Do biobanks need pharmacists? Support of pharmacy students to biobanking of human biological material for pharmaceutical research and development.

Domaradzki J, Majchrowska A, Cielecka-Piontek J, Walkowiak D Front Pharmacol. 2024; 15:1406866.

PMID: 38799162 PMC: 11117077. DOI: 10.3389/fphar.2024.1406866.

References
1.
Jimenez-Solem E, Petersen T, Hansen C, Hansen C, Lioma C, Igel C . Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients. Sci Rep. 2021; 11(1):3246. PMC: 7864944. DOI: 10.1038/s41598-021-81844-x. View

2.
Lambert S, Gil L, Jupp S, Ritchie S, Xu Y, Buniello A . The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation. Nat Genet. 2021; 53(4):420-425. PMC: 11165303. DOI: 10.1038/s41588-021-00783-5. View

3.
Topalovic M, Das N, Burgel P, Daenen M, Derom E, Haenebalcke C . Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. Eur Respir J. 2019; 53(4). DOI: 10.1183/13993003.01660-2018. View

4.
Alaa A, Bolton T, Di Angelantonio E, Rudd J, van der Schaar M . Cardiovascular disease risk prediction using automated machine learning: A prospective study of 423,604 UK Biobank participants. PLoS One. 2019; 14(5):e0213653. PMC: 6519796. DOI: 10.1371/journal.pone.0213653. View

5.
Schulz M, Chapman-Rounds M, Verma M, Bzdok D, Georgatzis K . Inferring disease subtypes from clusters in explanation space. Sci Rep. 2020; 10(1):12900. PMC: 7393364. DOI: 10.1038/s41598-020-68858-7. View